使用网络药理学,分子对接和分子动力学,从天然产品中发现用于治疗2型糖尿病的生物活性药物
Bita Rahmani1,2,3, Hossein Akbari4, Hadise Esmaeili5
1Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran. rahmanibita6@gmail.com.
Scientific reports
|December 5, 2025
概括
这项研究使用计算方法来识别天然化合物作为2型糖尿病 (T2DM) 的潜在治疗方法. 几种植物化合物显示出有前途的结合亲和性和稳定性,表明它们的治疗潜力.
科学领域:
- 药理学和生物信息学 药理学和生物信息学
- 自然产品化学 自然产品化学
- 计算机化药物发现技术
背景情况:
- 2型糖尿病 (T2DM) 给全球健康带来重大负担,需要新的治疗策略.
- 来自植物来源的天然化合物由于其多样化的生物活性和安全性,提供了潜在的替代治疗方法.
- 在的方法对于选天然产品对疾病标有价值.
研究的目的:
- 通过计算来评估天然化合物对T2DM相关基因的治疗潜力.
- 通过分子对接和模拟来确定T2DM治疗的有前途的天然产品领先候选人.
- 评估潜在的T2DM治疗剂的药理动力学和毒性概况.
主要方法:
- 从NPASS和ZINC12数据库对14个T2DM相关基因进行自然化合物的选.
- 进行了分子对接,药理动力学 (ADMET) 预测和网络药理学分析.
- 分子动力学模拟 (500nS) 针对排名最高的联结体-标复合体进行.
主要成果:
- 72种天然化合物显示出显著的结合亲和性,其中17种被确定为顶级候选物.
- 几种化合物,包括莫拉辛P,莫拉辛D,植物酸A,切利利思林,阿尔沃西迪布和乌尔索利克酸,表现出稳定的分子动态轨迹和有利的结合自由能量.
- 在ADMET分析中,发现了具有良好的口服生物可用性和最小毒性的有前途的候选物.
结论:
- 在体方法有效地确定了具有T2DM治疗潜力的天然产品.
- 选择的天然化合物,如莫拉辛P和切利利林,显示作为T2DM的替代或辅助疗法的希望.
- 进一步的实验验证至关重要,以确认这些已识别的化合物的临床应用的疗效和安全性.
更多相关视频
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
1.1K
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
2.7K
相关概念视频
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Principles of Drug Action
7.8K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
7.8K
Glucagon-like Receptor Agonists
820
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
820
Protein-protein Interfaces
14.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
14.4K
